← The Wire
RGNXNasdaq
REGENXBIO Inc.
Biological Products, (No Diagnostic Substances) · CIK 1590877
Develops gene therapy treatments using its NAV Technology Platform for genetic defects and therapeutic protein production
⚡ Elevated coverage
$344M
Market cap
$11.83
Last close
+12.9%
1D
+30.4%
5D
2.5M
Volume
Price · last 39 sessions+26.0%
May 4L $5.65 · H $11.83Jun 29
215
Total filings
Jun 29, 2026
Last filing
12/31
Fiscal year end
424B5424B5Feb 12, 2026424B5424B5Dec 9, 2024424B5424B5Mar 8, 2024424B5424B5Mar 6, 2024424B5424B5Sep 1, 2023424B5424B5Jan 8, 2021424B5424B5Jan 6, 2021424B5424B5Aug 10, 2018424B5424B5Aug 8, 2018424B5424B5Mar 23, 2017424B5424B5Mar 21, 2017
Insider Activity
In the 90 days to Mar 10, 2026: 1 sold $53K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 10, 2026 | Pakola SteveChief Medical Officer | Sell | 5,124 | $10.35 | $53K |
| Oct 9, 2025 | Simpson CurranChief Executive Officer | Sell | 20,811 | $12.62 | $263K |
| Sep 29, 2025 | Simpson CurranChief Executive Officer | Sell | 7,624 | $10.03 | $76K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 1 reputable article · skews ▲ positive.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance